Morinaga Milk Industry has filed a patent for an active ingredient that can improve mitochondrial function. The composition, which includes a bacterium of the genus Akkermansia, can also be used to suppress muscle inflammation or muscular atrophy. The patent claims a method of improving mitochondrial function by administering the bacterium or its products to a subject in need. GlobalData’s report on Morinaga Milk Industry gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Morinaga Milk Industry Co Ltd - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Morinaga Milk Industry, Lactobacilli-based drug compositions was a key innovation area identified from patents. Morinaga Milk Industry's grant share as of September 2023 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

Improving mitochondrial function using akkermansia bacterium or its products

Source: United States Patent and Trademark Office (USPTO). Credit: Morinaga Milk Industry Co Ltd

A recently filed patent (Publication Number: US20230248782A1) describes a method for improving mitochondrial function by administering a bacterium of the genus Akkermansia to a subject in need. The method also claims to have potential benefits in suppressing muscle inflammation and/or muscle atrophy.

The patent claims that by administering a bacterium of the genus Akkermansia, a subject's mitochondrial function can be improved. Mitochondria are responsible for producing energy in cells, and any dysfunction in their function can lead to various health issues. The bacterium of the genus Akkermansia, specifically Akkermansia muciniphila and Akkermansia glycaniphila, is suggested as a potential solution for enhancing mitochondrial function.

Additionally, the patent suggests that the method may also be beneficial for suppressing muscle inflammation and/or muscle atrophy. Muscle inflammation and atrophy can occur due to various factors, including aging, injury, or certain medical conditions. By administering the bacterium of the genus Akkermansia, the patent claims that these issues can be addressed.

The patent does not provide details on the specific administration method but mentions that the bacterium can be administered in the form of a food or a drink, as well as in the form of a pharmaceutical product. This suggests that the method can be easily incorporated into a subject's daily routine.

It is important to note that the claims made in the patent are based on the information provided and have not been independently verified. Further research and clinical trials would be necessary to validate the effectiveness and safety of this method. However, if proven successful, this method could potentially offer a novel approach to improving mitochondrial function and addressing muscle inflammation and atrophy in individuals in need.

To know more about GlobalData’s detailed insights on Morinaga Milk Industry, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.